Please login to the form below

Not currently logged in
Email:
Password:

Combination treatment

This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.

BMS unveils long-term results for Opdivo in kidney cancer

BMS unveils long-term results for Opdivo in kidney cancer

BMS also reported updated results from its CheckMate-214 trial, which evaluated Opdivo in combination with Yervoy (ipilimumab). ... At 42 months, the combination regimen continued to demonstrate superior overall survival, objective response rates,

Latest news

  • Roche files Tecentriq/Avastin combo in liver cancer Roche files Tecentriq/Avastin combo in liver cancer

    Roche has filed Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as a first-line treatment for unresectable hepatocellular carcinoma (HCC) – the most common form of liver cancer. ... In the IMbrave150 study, Tecentriq in combination

  • AZ says Brilinta hits the mark in new stroke trial AZ says Brilinta hits the mark in new stroke trial

    The combination treatment demonstrated a statistically significant reduction in the risk of the primary endpoint of stroke and death compared to aspirin alone – the full results are due to be presented ... Results of the phase 3 THALES trial showed

  • J&J wins another label expansion for Darzalex in Europe J&J wins another label expansion for Darzalex in Europe

    The European Commission has granted a marketing authorisation for the Darzalex-VTd combination as a treatment of newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT). ... This includes another  combination regimen, with

  • J&J pushes to expand Imbruvica label after clinical success J&J pushes to expand Imbruvica label after clinical success

    If successful, J&J, through its Janssen unit, will get approval to sell Imbruvica for use as a first-line treatment in combination with rituximab. ... That effort gained a boost last year when the US Food and Drug Administration (FDA)   approved

  • BMS expands collaboration with Nektar, sending shares soaring BMS expands collaboration with Nektar, sending shares soaring

    As an answer to Opdivo’s apparent inability to demonstrate benefit in this area as a monotherapy, BMS has looked to combination therapies of its PD-1 inhibitor. ... Although the results were promising, BMS could find it hard to convince clinicians that

More from news
Approximately 0 fully matching, plus 260 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin

  • Pharma deals in April 2015 Pharma deals in April 2015

    No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL.  . ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.

  • Pharma deals during July 2014 Pharma deals during July 2014

    Underscoring its strategy in focusing the business in the core areas, in July Baxter also announced the acquisition of AesRx, a private US company developing a phase II stage prophylactic treatment ... The acquisition of Almirall's respiratory business

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    And again, matching drugs that work well together will be crucial going forward: “Combination treatment will be a critical component; how best to put these drugs together with other checkpoint inhibitors, ... This includes people with NSCLC who have a

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    First-line treatment in China combines surgery and chemotherapy for 24.5 per cent of patients. ... In China there has been a rise in the use of Xeloda in combination with docetaxel as a second and third-line treatment.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Oncosec

    body.  OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed

  • Marketing strategy in complex environments

    The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving

  • Raising Awareness: It’s World COPD Day today!

    Inhaled corticosteroids (ICS)  are another COPD treatment used to reduce inflammation in the lungs. ... Overuse of inhaled corticosteroids? The treatment guidelines set out by GOLD (1) have suggested that an ICS should only be prescribed after single

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics